Incidence and prognostic impact of HER2‐positivity loss after dual HER2‐directed neoadjuvant therapy for HER2+ breast cancer

BACKGROUND: Loss of HER2 “positivity” can occur in patients with residual disease after neoadjuvant treatment, but the incidence of HER2‐positivity loss after neoadjuvant dual HER2‐targeted treatment plus chemotherapy, the current standard‐of‐care for most early stage HER2‐positive breast cancers, i...

Descripción completa

Detalles Bibliográficos
Autores principales: LeVee, Alexis, Spector, Kellie, Larkin, Brigid, Dezem, Felipe, Plummer, Jasmine, Dadmanesh, Farnaz, Patil, Sujata, McArthur, Heather L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10225224/
https://www.ncbi.nlm.nih.gov/pubmed/36971049
http://dx.doi.org/10.1002/cam4.5817

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10225224/
https://www.ncbi.nlm.nih.gov/pubmed/36971049
http://dx.doi.org/10.1002/cam4.5817

Ejemplares similares